

Victor L J L Thijssen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5337157/publications.pdf>

Version: 2024-02-01

94
papers

5,062
citations

76326

40
h-index

91884

69
g-index

96
all docs

96
docs citations

96
times ranked

7723
citing authors

#	ARTICLE	IF	CITATIONS
1	Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15975-15980.	7.1	424
2	Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB Journal, 2006, 20, 621-630.	0.5	237
3	Antiangiogenesis Therapy for Endometriosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1089-1095.	3.6	215
4	Tumor Cells Secrete Galectin-1 to Enhance Endothelial Cell Activity. Cancer Research, 2010, 70, 6216-6224.	0.9	210
5	The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy. Pharmacological Reviews, 2015, 67, 441-461.	16.0	190
6	Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 235-247.	7.4	188
7	Multifunctional Nanoemulsion Platform for Imaging Guided Therapy Evaluated in Experimental Cancer. ACS Nano, 2011, 5, 4422-4433.	14.6	183
8	The Galectin Profile of the Endothelium. American Journal of Pathology, 2008, 172, 545-553.	3.8	175
9	Structural Changes of Atrial Myocardium During Chronic Atrial Fibrillation. Cardiovascular Pathology, 2000, 9, 17-28.	1.6	122
10	Blocking of Frizzled Signaling With a Homologous Peptide Fragment of Wnt3a/Wnt5a Reduces Infarct Expansion and Prevents the Development of Heart Failure After Myocardial Infarction. Circulation, 2011, 124, 1626-1635.	1.6	122
11	Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood, 2007, 110, 2819-2827.	1.4	118
12	Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Molecular Cancer, 2010, 9, 152.	19.2	112
13	Structural remodelling during chronic atrial fibrillation: act of programmed cell survival. Cardiovascular Research, 2001, 52, 14-24.	3.8	103
14	17 β -Estradiol Antagonizes Cardiomyocyte Hypertrophy by Autocrine/Paracrine Stimulation of a Guanylyl Cyclase A Receptor-Cyclic Guanosine Monophosphate-Dependent Protein Kinase Pathway. Circulation, 2004, 109, 269-276.	1.6	99
15	Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11451-11456.	7.1	93
16	Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resistance Updates, 2016, 25, 26-37.	14.4	88
17	Galectin-9 in tumor biology: A jack of multiple trades. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 177-185.	7.4	87
18	PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nature Medicine, 2014, 20, 741-747.	30.7	86

#	ARTICLE	IF	CITATIONS
19	Angiogenesis gene expression profiling in xenograft models to study cellular interactions. <i>Experimental Cell Research</i> , 2004, 299, 286-293.	2.6	76
20	Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?. <i>Frontiers in Immunology</i> , 2018, 9, 3107.	4.8	76
21	High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. <i>British Journal of Cancer</i> , 2007, 96, 1888-1895.	6.4	70
22	Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2016, 11, e0157830.	2.5	69
23	Increased expression of distinct galectins in multiple sclerosis lesions. <i>Neuropathology and Applied Neurobiology</i> , 2011, 37, 654-671.	3.2	68
24	Involvement of galectin-1 in reproduction: past, present and future. <i>Human Reproduction Update</i> , 2014, 20, 175-193.	10.8	67
25	Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth. <i>Journal of Pathology</i> , 2018, 246, 447-458.	4.5	67
26	Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. <i>British Journal of Cancer</i> , 2011, 104, 1185-1192.	6.4	65
27	Vascular galectins: Regulators of tumor progression and targets for cancer therapy. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 547-558.	7.2	65
28	Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium. <i>Molecular Human Reproduction</i> , 2006, 12, 367-375.	2.8	60
29	Combining angiogenesis inhibition and radiotherapy: A double-edged sword. <i>Drug Resistance Updates</i> , 2012, 15, 173-182.	14.4	60
30	Different angioregulatory activity of monovalent galectin-9 isoforms. <i>Angiogenesis</i> , 2018, 21, 545-555.	7.2	56
31	Galectin-1 and -9 in angiogenesis: A sweet couple. <i>Glycobiology</i> , 2014, 24, 915-920.	2.5	55
32	Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor. <i>Circulation Research</i> , 2010, 106, 155-165.	4.5	54
33	Tetraspanin CD63 Promotes Vascular Endothelial Growth Factor Receptor 2- β 1 Integrin Complex Formation, Thereby Regulating Activation and Downstream Signaling in Endothelial Cells in Vitro and in Vivo. <i>Journal of Biological Chemistry</i> , 2013, 288, 19060-19071.	3.4	52
34	Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer. <i>PLoS ONE</i> , 2015, 10, e0129119.	2.5	52
35	Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 284-292.	3.8	48
36	Angiogenic Profile of Breast Carcinoma Determines Leukocyte Infiltration. <i>Clinical Cancer Research</i> , 2004, 10, 7171-7178.	7.0	47

#	ARTICLE	IF	CITATIONS
37	Uterine NK Cells Are Critical in Shaping DC Immunogenic Functions Compatible with Pregnancy Progression. PLoS ONE, 2012, 7, e46755.	2.5	47
38	Epigenetic Regulation of Galectin-3 Expression by β 1 Integrins Promotes Cell Adhesion and Migration. Journal of Biological Chemistry, 2012, 287, 44684-44693.	3.4	46
39	MicroRNAs in the tumor endothelium: Novel controls on the angioregulatory switchboard. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 87-96.	7.4	45
40	The Anti-angiogenic Peptide Anginex Greatly Enhances Galectin-1 Binding Affinity for Glycoproteins. Journal of Biological Chemistry, 2011, 286, 13801-13804.	3.4	45
41	Anginex-Conjugated Liposomes for Targeting of Angiogenic Endothelial Cells. Bioconjugate Chemistry, 2007, 18, 785-790.	3.6	41
42	Analysis of altered gene expression during sustained atrial fibrillation in the goat. Cardiovascular Research, 2002, 54, 427-437.	3.8	39
43	Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer. Molecular Cancer, 2015, 14, 71.	19.2	39
44	Expression, Regulation and Function of Human Metallothioneins in Endothelial Cells. Journal of Vascular Research, 2014, 51, 231-238.	1.4	38
45	CXCR4+ Dendritic cells promote angiogenesis during embryo implantation in mice. Angiogenesis, 2013, 16, 417-427.	7.2	36
46	Galectins in tumor angiogenesis. Annals of Translational Medicine, 2014, 2, 90.	1.7	33
47	Interfering with UDP-GlcNAc Metabolism and Heparan Sulfate Expression Using a Sugar Analogue Reduces Angiogenesis. ACS Chemical Biology, 2013, 8, 2331-2338.	3.4	32
48	Combining radiotherapy with sunitinib: lessons (to be) learned. Angiogenesis, 2015, 18, 385-395.	7.2	32
49	Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain, 2018, 141, 3377-3388.	7.6	32
50	Profiling Lgals9 Splice Variant Expression at the Fetal-Maternal Interface: Implications in Normal and Pathological Human Pregnancy. Biology of Reproduction, 2013, 88, 22.	2.7	31
51	Functional characterization of a STAT3-dependent dendritic cell-derived CD14 ⁺ cell population arising upon IL-10-driven maturation. Oncoimmunology, 2013, 2, e23837.	4.6	31
52	A common sugar-nucleotide-mediated mechanism of inhibition of (glycosamino)glycan biosynthesis, as evidenced by 6-Fa-GalNAc (Ac ₃). FASEB Journal, 2015, 29, 2993-3002.	0.5	31
53	Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer. Frontiers in Immunology, 2018, 9, 1598.	4.8	31
54	Temporal and Spatial Variations in Structural Protein Expression During the Progression From Stunned to Hibernating Myocardium. Circulation, 2004, 110, 3313-3321.	1.6	29

#	ARTICLE	IF	CITATIONS
55	Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. <i>Glycobiology</i> , 2009, 19, 68-75.	2.5	29
56	Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. <i>Cancer Medicine</i> , 2015, 4, 1003-1015.	2.8	29
57	Anti-angiogenesis and anti-tumor activity of recombinant anginex. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 1073-1078.	2.1	28
58	Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. <i>Oncotarget</i> , 2016, 7, 76613-76627.	1.8	27
59	The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. <i>Angiogenesis</i> , 2017, 20, 217-232.	7.2	26
60	Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. <i>Biochemical and Biophysical Research Communications</i> , 2005, 333, 1261-1268.	2.1	25
61	Galectin Expression Profiling Identifies Galectin-1 and Galectin-9 ¹ 5 as Prognostic Factors in Stage I/II Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e107988.	2.5	23
62	Troponin I Isoform Expression in Human and Experimental Atrial Fibrillation. <i>Circulation</i> , 2004, 110, 770-775.	1.6	22
63	Targeted gene-delivery strategies for angiostatic cancer treatment. <i>Trends in Molecular Medicine</i> , 2007, 13, 200-209.	6.7	22
64	A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies. <i>International Journal of Cancer</i> , 2016, 139, 824-835.	5.1	21
65	A low frequency of lymph node metastasis in clear cell renal cell carcinoma is related to low lymphangiogenic activity. <i>BJU International</i> , 2009, 103, 1626-1631.	2.5	19
66	Targeting Tumor Vascular CD99 Inhibits Tumor Growth. <i>Frontiers in Immunology</i> , 2019, 10, 651.	4.8	17
67	Galectins in Endothelial Cell Biology and Angiogenesis: The Basics. <i>Biomolecules</i> , 2021, 11, 1386.	4.0	17
68	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 161.	8.6	16
69	Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango. <i>Current Pharmaceutical Design</i> , 2007, 13, 3576-3583.	1.9	15
70	Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2029-2040.	4.2	13
71	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. <i>PLoS ONE</i> , 2021, 16, e0244736.	2.5	12
72	Development of transient radioresistance during fractionated irradiation in vitro. <i>Radiotherapy and Oncology</i> , 2020, 148, 107-114.	0.6	12

#	ARTICLE	IF	CITATIONS
73	Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts. <i>Cancers</i> , 2019, 11, 261.	3.7	11
74	Examination of the Role of Galectins During In Vivo Angiogenesis Using the Chick Chorioallantoic Membrane Assay. <i>Methods in Molecular Biology</i> , 2015, 1207, 305-315.	0.9	10
75	Metallated phthalocyanines and their hydrophilic derivatives for multi-targeted oncological photodynamic therapy. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2022, 234, 112500.	3.8	8
76	Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients. <i>Pharmaceuticals</i> , 2022, 15, 796.	3.8	8
77	Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies. <i>Molecular Oncology</i> , 2021, 15, 901-914.	4.6	7
78	Combining Radiation Therapy With Interferons: Back to the Future. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 56-69.	0.8	6
79	Examination of the Role of Galectins and Galectin Inhibitors in Endothelial Cell Biology. <i>Methods in Molecular Biology</i> , 2015, 1207, 285-291.	0.9	5
80	Chemokines modulate glycan binding and the immunoregulatory activity of galectins. <i>Communications Biology</i> , 2021, 4, 1415.	4.4	5
81	Introduction to special issue: Glycans in vascular biology. <i>Glycobiology</i> , 2014, 24, 1235-1236.	2.5	4
82	Angiostatic Cancer Therapy by Targeting Galectins in the Tumor Vasculature. <i>ACS Symposium Series</i> , 2012, , 233-247.	0.5	3
83	Introduction to special issue: Galectins go with the flow. <i>Glycobiology</i> , 2014, 24, 885-885.	2.5	3
84	Method to Study the Role of Galectins in Angiogenesis In Vivo Using the Chick Chorioallantoic Membrane Assay. <i>Methods in Molecular Biology</i> , 2022, 2442, 621-633.	0.9	1
85	One less concern. <i>Nature</i> , 2009, 457, 628-628.	27.8	0
86	Abstract 3490: Identification and characterization of novel galectin-9 splice variants in endothelial cells. , 2011, , .		0
87	Galectin-9. , 2016, , 1-6.		0
88	Galectin-9. , 2018, , 1991-1996.		0
89	Abstract 3738: A STING independent type-1 interferon response induced by fractionated radiotherapy coincides with altered tumor growth and clonogenicity. , 2019, , .		0
90	Examination of the Role of Galectins and Galectin Inhibitors in Endothelial Cell Biology. <i>Methods in Molecular Biology</i> , 2022, 2442, 655-662.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. , 2021, 16, e0244736.		0
92	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. , 2021, 16, e0244736.		0
93	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. , 2021, 16, e0244736.		0
94	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. , 2021, 16, e0244736.		0